Patents Assigned to Shionogi & Co., Ltd.
-
Publication number: 20250099474Abstract: The present invention provides a pharmaceutical composition containing a coronavirus 3CL protease inhibitor for treating novel coronavirus infections (COVID-19). A pharmaceutical composition for treating novel coronavirus infections (COVID-19) is provided, the composition containing, as an active ingredient, a complex that contains: a compound represented by Formula (I): and fumaric acid.Type: ApplicationFiled: January 18, 2023Publication date: March 27, 2025Applicant: Shionogi & Co., Ltd.Inventors: Ryosuke SHIMIZU, Yumiko MATSUO, Takahiro FUKUHARA, Keita FUKAO, Takayuki KURODA, Haruaki NOBORI, Toru ISHIBASHI
-
Publication number: 20250090048Abstract: A system has an output for outputting an acoustic signal generated by amplitude modulation, the acoustic signal having an amplitude change corresponding to the frequency of gamma waves, a memory for storing information of the acoustic signal output by the output, and a transmission for transmitting a notification based on the information stored by the memory to a apparatus external to the system.Type: ApplicationFiled: December 3, 2024Publication date: March 20, 2025Applicants: Pixie Dust Technologies, Inc., Shionogi & Co., Ltd.Inventors: Yoshiki NAGATANI, Kazuki TAKAZAWA, Haruki KATAYAMA
-
Publication number: 20250092056Abstract: The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.Type: ApplicationFiled: April 7, 2023Publication date: March 20, 2025Applicant: Shionogi & Co., Ltd.Inventors: Jun Sato, Hiromitsu SHIBAYAMA, Keiichiro HIRAI, Yuto UNOH, Shota UEHARA, Shuji YONEZAWA, Kana KURAHASHI, Eiichi KOJIMA
-
Publication number: 20250073226Abstract: Provided are a new pharmaceutical composition and a method for treating and/or preventing autism spectrum disorder, fragile X syndrome, and/or an autism spectrum disorder-like symptom. A pharmaceutical composition for the treatment and/or prevention of autism spectrum disorder, fragile X syndrome, and/or an autism spectrum disorder-like symptom, comprising buprenorphine or a pharmaceutically acceptable salt thereof and/or morphine or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 21, 2022Publication date: March 6, 2025Applicants: OSAKA UNIVERSTIY, SHIONOGI & CO., LTD.Inventors: Yukio AGO, Hidekuni YAMAKAWA, Atsushi NAKAMURA
-
Patent number: 12227509Abstract: The present invention provides a compound represented by a following formula. A compound represented by, wherein R1 is hydrogen, hydroxy, or the like; R2a and R2b may be taken together with an adjacent carbon atom to form ring B, ring B is a substituted or unsubstituted non-aromatic carbocycle or a substituted or unsubstituted non-aromatic heterocycle; R3a is hydrogen, halogen, hydroxy, or the like; R3b is hydrogen, halogen, hydroxy, or the like; R4a is a group represented by formula: L3 is a single bond or substituted or unsubstituted alkylene, R7 is hydrogen, halogen, hydroxy, or the like, and R4b is halogen, cyano, carboxy, or the like, or its pharmaceutically acceptable salt.Type: GrantFiled: January 10, 2020Date of Patent: February 18, 2025Assignee: SHIONOGI & CO., LTD.Inventors: Yusuke Tateno, Manabu Katou, Toshihiro Wada
-
Publication number: 20250041279Abstract: Provided is a pharmaceutical composition for treating and/or preventing at least one of heart diseases, heart disease complications, skeletal muscle diseases, and skeletal muscle conditions, the pharmaceutical composition having an excellent ACC2-selective inhibitory effect and having no side effects such as an increase in plasma triglyceride or a decrease in platelet concentration. A pharmaceutical composition for treating and/or preventing at least one of heart diseases, heart disease complications, skeletal muscle diseases, and skeletal muscle conditions, the pharmaceutical composition comprising a compound represented by Formula (I): wherein R1 is haloalkyl or non-aromatic carbocyclyl, R2 is a hydrogen atom or halogen, R3 is halogen, ring A is a group represented by the formula: —L1-is —O—(CH2)2, —(CH2)2—, or the like, R4 is alkyl or haloalkyl, and R5 is alkylcarbonyl or carbamoyl, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 18, 2022Publication date: February 6, 2025Applicant: SHIONOGI & CO., LTD.Inventors: Yasunobu YOSHIDA, Mai UNO USUI, Atsuyuki SHIMAZAKI, Hideo YUKIOKA, Yuto KASHIWAGI, Tomomi YAMADA
-
Publication number: 20250025459Abstract: The present invention provides a medicament useful in treatment and/or prevention, etc. of COVID-19. Provided is a medicament characterized by combining (A) a compound represented by Formula (I): wherein Y is N; R1 is substituted or unsubstituted aromatic heterocyclyl; R2 is substituted or unsubstituted 6-membered aromatic carbocyclyl; R3 is substituted or unsubstituted aromatic heterocyclyl; —X— is —NH—; m is 0 or 1; R5a is a hydrogen atom; R5b is a hydrogen atom; n is 1; R4a is a hydrogen atom; and R4b is a hydrogen atom, or a pharmaceutically acceptable salt thereof; and (B) a COVID-19 exacerbation suppressant.Type: ApplicationFiled: November 25, 2022Publication date: January 23, 2025Applicant: Shionogi & Co., Ltd.Inventors: Ryuichi YANO, Atsuko YAMAMOTO, Haruaki NOBORI, Teruhisa KATO
-
Publication number: 20250026765Abstract: Provided are compounds having a serotonin 5-HT2A receptor antagonism and/or inverse agonism, pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising thereof.Type: ApplicationFiled: September 21, 2022Publication date: January 23, 2025Applicant: Shionogi & Co., Ltd.Inventors: Tatsuhiko UENO, Rina YASUI
-
Publication number: 20240400560Abstract: The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Provided is a compound represented by Formula (I): wherein carbon atom a and carbon atom b are each a carbon atom constituting ring A, the ring A is substituted aromatic carbocycle or the like, R1 is substituted or unsubstituted aromatic heterocyclyl or the like, R2 is substituted or unsubstituted 6-membered aromatic carbocyclyl or the like, m is 1 or the like, R5as are each independently a hydrogen atom or the like, R5bs are each independently a hydrogen atom or the like, n is 1 or the like, R4a is a hydrogen atom or the like, and R4a is a hydrogen atom or the like. Alternatively, provided is a pharmaceutically acceptable salt of the compound.Type: ApplicationFiled: September 15, 2022Publication date: December 5, 2024Applicants: Shionogi & Co., Ltd., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITYInventors: Yoshiyuki TAODA, Shota UEHARA, Yuseke SAKO, Keiichiro HIRAI
-
Publication number: 20240374587Abstract: A pharmaceutical preparation characterized by combination of (A) and (B) is useful for the prevention and treatment of a disease related to anti-obesity effect, wherein (A) is a compound represented by formula: or a pharmaceutically acceptable salt thereof, and (B) is at least one agent selected from the group consisting of agents having anti-obesity action, agents for controlling blood glucose level, agents for controlling cholesterol and/or triglyceride in blood, and agents for controlling blood pressure.Type: ApplicationFiled: September 7, 2022Publication date: November 14, 2024Applicant: Shionogi & Co., Ltd.Inventors: Kosuke TAKEMOTO, Keisuke KUSUMOTO
-
Patent number: 12139489Abstract: The present invention provides a compound represented by Formula (I): wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R1 is halogen or the like; R2a and R2b are each independently hydrogen or the like; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.Type: GrantFiled: March 22, 2023Date of Patent: November 12, 2024Assignee: Shionogi & Co., Ltd.Inventors: Yoshiyuki Taoda, Yuto Unoh
-
Publication number: 20240366622Abstract: The present invention provides a preparation that is minimally colored through irradiation with light by coating a preparation containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, or a crystal thereof with a light stabilizing substance and a polymer, particularly with one or more of titanium oxide and talc used as the light stabilizing substance and hypromellose used as the polymer.Type: ApplicationFiled: July 15, 2024Publication date: November 7, 2024Applicant: Shionogi & Co., Ltd.Inventors: Naomi HAYASHI, Masato GOMI, Shohei AIKAWA
-
Publication number: 20240352015Abstract: The present invention provides a compound represented by Formula (I): wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R1 is halogen or the like; R2a and R2b are each independently hydrogen or the like; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.Type: ApplicationFiled: June 26, 2024Publication date: October 24, 2024Applicant: Shionogi & Co., Ltd.Inventors: Yoshiyuki TAODA, Yuto UNOH
-
Patent number: 12098151Abstract: The present invention provides a compound having antiviral activity, especially having arenavirus proliferation inhibitory activity, and/or a medicament comprising the compound. More preferably, the present invention provides a compound having proliferation inhibitory activity on the Old World arenaviruses such as Luna virus, Lassa virus, and lymphocytic choriomeningitis virus and/or the New World arenaviruses such as Junin virus, and/or a medicament comprising the compound.Type: GrantFiled: September 30, 2022Date of Patent: September 24, 2024Assignees: NATIONAL UNIVERSITY COPORATION HOKKAIDO UNIVERSITY, SHIONOGI & CO., LTD.Inventors: Akihiro Ishii, Akihiko Sato, Makoto Kawai, Yoshiyuki Taoda
-
Publication number: 20240309002Abstract: The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: or the like; y is 0 or 1; R1 is hydrogen or the like; R2a and R2b are taken together with an adjacent carbon atom to form ring B; ring B is a substituted or unsubstituted non-aromatic carbocycle or the like; R3a is hydrogen or the like; R3b is hydrogen or the like; R4a is represented by formula: L1 is a single bond or the like; L2 is —C(?O)— or the like; La is a single bond or the like; R7 is substituted or unsubstituted alkyl or the like; R4b is substituted or unsubstituted alkyl or the like; R4c is each independently halogen or the like.Type: ApplicationFiled: May 16, 2024Publication date: September 19, 2024Applicant: Shionogi & Co., Ltd.Inventors: Kouhei NODU, Yusuke Tateno, Kengo Masuda, Yuji Nishiura, Yoshikazu Sasaki, Yu Hinata
-
Publication number: 20240279238Abstract: Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1?,2?:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.Type: ApplicationFiled: April 9, 2024Publication date: August 22, 2024Applicants: Shionogi & Co., Ltd., ViiV Healthcare CompanyInventors: Brian A. JOHNS, Takashi KAWASUJI, Teruhiko TAISHI, Yoshiyuki TAODA
-
Patent number: 12064438Abstract: The present invention provides a preparation that is minimally colored through irradiation with light by coating a preparation containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, or a crystal thereof with a light stabilizing substance and a polymer, particularly with one or more of titanium oxide and talc used as the light stabilizing substance and hypromellose used as the polymer.Type: GrantFiled: November 15, 2018Date of Patent: August 20, 2024Assignee: SHIONOGI & CO., LTD.Inventors: Naomi Hayashi, Masato Gomi, Shohei Aikawa
-
Publication number: 20240252505Abstract: The present invention provides a solid dosage form having good stability, suspensibility in water and fluidity by preparing a solid dosage form containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a stabilizer, a sugar alcohol and/or a sugar, a water-soluble polymer and an inorganic substance.Type: ApplicationFiled: February 7, 2024Publication date: August 1, 2024Applicant: Shionogi & Co., Ltd.Inventors: Naoya MIZUTANI, Masayuki MORIMOTO, Maki OKABE, Masaaki ITO, Go KIMURA
-
Publication number: 20240217966Abstract: The present invention relates to a compound that has GLP-1 receptor agonist activity and is useful as a therapeutic or prophylactic agent for diseases associated with the GLP-1 receptor, or a pharmaceutically acceptable salt thereof, and relates to a pharmaceutical composition containing the compound or its pharmaceutically acceptable salt. Provided is a compound represented by formula (I): wherein A1 is C(R5) or the like, A2 is C(R6) or the like, A3 is C(R7) or the like, R5, R6, and R7 are each independently a hydrogen atom or the like, R1 is carboxy or the like, R2 is substituted or unsubstituted alkyl or the like, —X— is —O— or the like, the ring represented by: is a ring represented by: ?and the like wherein R10 is each independently halogen or the like, s is 0 or the like, R13 is each independently a hydrogen atom or the like, and R3 is substituted or unsubstituted aromatic carbocyclyl or the like, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 23, 2022Publication date: July 4, 2024Applicant: Shionogi & Co., Ltd.Inventors: Misato KITAMURA FUJIWARA, Shomitsu MAENO, Yuji NISHIURA
-
Patent number: 12024519Abstract: The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: is or the like. The symbols are defined in the specification. The compounds of the present invention have MGAT2 inhibitory activity, and are useful as a medicine for treatment of MGAT2-associated diseases including obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyper-VLDL-triglyceridemia, hyperfattyacidemia, diabetes mellitus, and arteriosclerosis.Type: GrantFiled: November 12, 2021Date of Patent: July 2, 2024Assignee: SHIONOGI & CO., LTD.Inventors: Kouhei Nodu, Yusuke Tateno, Kengo Masuda, Yuji Nishiura, Yoshikazu Sasaki